Analyst consensus rating
Akari Therapeutics Analyst Rating: Strong Buy
Direct answer
Akari Therapeutics's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.50.
Forecast evidence checked November 17, 2026.
Get free Akari Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.51
- Average price target
- $25.50
- High price target
- $30.00
- Low price target
- $19.50
- Low target gap
- +199.5%
- Target upside
- +291.7%
- High target gap
- +360.8%
- Target range width
- 161.3%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- November 17, 2026
- Valid through
- November 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Akari Therapeutics?
Akari Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $25.50.
How far are Akari Therapeutics's low and high targets from the recorded price?
The low target implies +199.5%, while the high target implies +360.8%.
How many analysts are included in Akari Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Akari Therapeutics's target upside or downside calculated?
The average target of $25.50 is divided by the recorded price of $6.51, then one is subtracted to produce +291.7%. This does not guarantee a future return.
When was Akari Therapeutics's analyst forecast verified?
The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.